This Article Has Been Medically Approved By Dr. Timothy Connall

The International Society of Aesthetic Plastic Surgery, The Aesthetic Society, and The Aesthetic Surgery Education and Research Foundation recently issued a joint advisory statement on the diagnosis and management of patients with breast implants and concurrent systemic disease. This statement is based on the most current scientific evidence. The positions expressed are the consensus of a vast majority of plastic surgeons in the U.S. and around the world. The approach detailed is consistent with how I manage these patients at Esprit. 

I treat patients with concerns of “breast implant illness” (BII)- Some are from my practice, and I was the surgeon that placed the breast implants, and some had their implants placed elsewhere. I think it is imperative that all patients get the most compassionate, thorough, and evidence-based care possible. There are many misconceptions perpetuated on the internet and social media about BII. I think this advisory statement puts the topic in perspective, and that it should be read carefully by all women considering treatment for BII. 

I am here to help patients with their implants, including when they want their implants removed. During a consultation I collaborate with each patient to decide the best treatment plan. Sometimes implant removal is all that’s done. In some cases, implant removal and capsulectomy are performed. I recognize the heavy burden that BII places on patients. I am committed to giving all such patients the best treatment, and the best breasts possible after surgery.   


Timothy P. Connall, MD, FACS

Joint Safety Statement of the International Society of Aesthetic Plastic Surgery (ISAPS), The Aesthetic Society, and The Aesthetic Surgery Education and Research Foundation (ASERF)

Patient Safety Advisory – Breast Implant Removal and Capsulectomy

May 9, 2023

There has been a worldwide increase in the number of patients requesting implant removal for a variety of systemic symptoms that they attribute to their implants. This has been referred to as Silicone Incompatibility Syndrome (SIS), Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA), and Breast Implant Illness (B11).1 In the US, the Food and Drug Administration (FDA) has included systemic symptoms in a box warning that is required for all implants sold in the US which states, “Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others. Individual patient risk for the development of these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.”2

Patients with self-described symptoms request removal of the implant and capsule, “en bloc”. Their concern is that toxins from the implant, such as heavy metals, including platinum, silicone, and/or bacteria and fungus, could be in the capsules and failure to remove the capsule would leave toxins behind and could preclude symptom improvement. For that reason, they seek out surgeons who guarantee total en bloc capsulectomy and this is perpetuated on some social media sites as well as by surgeons who promote themselves as “explant experts”.3

What We Know

  • Systemic symptoms patients attribute to their breast implants have been reported with all types of implants: saline and gel filled, smooth and textured surfaces, and has been reported with implants from every manufacturer
  • Over 100 symptoms have been reported, in no specific configuration.
  • Some patients will experience symptom improvement with implant removal.

What is the Data?

The Aesthetic Surgery Journal has published four papers from an ASERF-funded study, “Systemic Symptoms in Women – Biospecimen Analysis Study.” This study, with Drs. Caroline Glicksman and Patricia McGuire as principal investigators, is the first prospective, blinded study comparing women with self-described BIi to two control groups. The study evaluated symptom surveys, NIH-validated patient-reported outcome measures, and biospecimens (peripheral blood and implant capsules) for consistent, objective, measurable differences between the symptomatic cohort and the two control groups (women with implants without systemic symptoms they attribute to their implants, and women undergoing cosmetic mastopexy who have never had any implanted medical device) which could be used to make a diagnosis or point to a cause of symptoms in these patients. 4-7

1. The self-described BIi cohort reported statistically significantly higher symptoms at baseline from the two control cohorts.

2. The BIi cohort experienced rapid symptom improvement after implant removal which was sustained through one year of follow-up. The symptom improvement was independent of whether part or all the capsule was removed. There was no statistical difference in reported symptoms between the two control groups at any time point.
3. There was no measurable difference in the biospecimens between the cohorts including heavy metals testing and next generation sequencing (PCR) for bacterial and fungal DNA of the implant surface or capsule.
4. Recently presented data from a parallel study in Australia, with Drs. Anand Deva and Mark Magnusson as principal investigators, has shown similar results with symptom improvement after implant removal, independent of the type of capsulectomy performed.8
5. A study by Byrd and Nissen in the Netherlands prospectively followed patients undergoing implant removal and showed that symptom improvement occurred even with no capsule removed in subjects
with no other indication for capsulectomy. 9

Terminology is Important

  • The term en bloc describes a procedure for malignancy where a tumor is removed with a margin of uninvolved tissue. This term should not be used for a capsulectomy performed in the absence of malignancy.10
  • The often self-reported term BIi implies a causation by breast implants when there is currently no direct evidence of causation, only a potential association. A more accurate characterization would be to use the term “Systemic Symptoms Associated with Breast Implants (SSBI)”.

What Does this Mean for Plastic Surgeons and for our Patients?

As board-certified plastic surgeons, we should practice evidence-based medicine proven to promote our patient’s safety and comfort. The absolute indication for en bloc capsulectomy is removal of an implant and capsule in the presence of capsular malignancy. Relative indications for total capsulectomy are capsular contracture, rupture of a gel implant, and possibly with removal and exchange of textured implants. There is currently no good peer-reviewed evidence that capsulectomy is required for symptom improvement in the absence of other indications. Patient preference may be considered with appropriate informed consent. Capsulectomy is a more invasive procedure, may be more expensive, and may carry higher risks.

  • Surgeons who state that en bloc capsulectomy is required for symptom improvement should not do so without the scientific data to support their claims and potentially violate ethical standards, as it could lead patients to undergo surgical procedures that may not be indicated.11
  • Surgeons promoting themselves as “explant experts” who have no additional training or other basis to deem them more of an expert than other board-certified plastic surgeons, should cease marketing themselves as such.
  • Surgeons should keep abreast of scientific knowledge (AMA Principles of Medical Ethics).
  • Surgeons should not falsely represent a skill set; ASPS Code of Ethics G-9: Contains a representation or statement of opinion as to the superior quality of professional services which is not susceptible to verification by the public or contains a statement representing that the Member possesses skills or provides services superior to those of other physicians with similar training unless such representation can be factually substantiated.

SSBI remain a diagnosis of exclusion so patients should have an appropriate medical evaluation to rule out other causes prior to surgery. Patients should be given educated choices using up-to-date, scientific data including removal of their implants with or without capsulectomy with the risks and benefits fully explained. It is likely patients will see at least partial symptom improvement after implant removal and their improvement may occur with partial capsulectomy, or no capsulectomy. Further prospective research is necessary, and guidance may change as more data becomes available.12

Safety Information for Patients

1. Breast implants are not lifetime devices and require regular follow-ups with your plastic surgeon.2
2. Implant integrity should be evaluated with high-resolution ultrasound (HRUS) or MRI five years after implant placement and every 2-3 years after.2
3. Any persistent symptoms that occur in patients with breast implants should be evaluated for other medical diseases prior to consideration of undergoing implant removal surgery.
4. For patients who develop symptoms that they attribute to their breast implants, if no other cause is found, it is likely that they will see at least partial symptom improvement after implant removal. The symptom improvement may occur with no or partial capsulectomy which is a procedure that is less invasive, less expensive and may carry lower risk.
5. Patients should seek out board-certified plastic surgeons for any concerns with their breast implants.


1. Magnusson MR, Cooter RD, Rakhorst H, et al. Breast Implant Illness: A Way Forward. Plastic and Reconstructive Surgery. 2019; 143(3S): 74S-81S
3. accessed 5/2/2023
4. Glicksman C, McGuire P, Kadin M, Lawrence M, Haws M, Newby J, Ferenz S, Sung J, Wixtrom R.
Impact of Capsulectomy Type on Post-Explantation Systemic Symptom Improvement: Findings From the ASERF Systemic Symptoms in Women – Biospecimen Analysis Study: Part 1. Aesthet Surg J. 2022; 42(7): 809-819;
5. Wixtrom R, Glicksman C, Kadin M, et al. Heavy Metals in Breast Implant Capsules and Breast Tissue: Findings From the Systemic Symptoms in Women – Biospecimen Analysis Study: Part 2. Aesthet Surg J. 2022; 42(9): 1067-1076;
6. McGuire P, Glicksman C, Wixtrom R, et al. Microbes, Histology, Blood Analysis, Enterotoxins, and Cytokines: Findings From the ASERF Systemic Symptoms in Women – Biospecimen Analysis Study: Part 3. Aesthet Surg J. 2023; 43(2): 230-244;
7. Glicksman C, McGuire P, Kadin M, Barnes K, Wixtrom R, Lawrence M, Haws M, Ferenz S, Sung J, Hamilton R, Faasse K. Longevity of Post-Explantation Systemic Symptom Improvement and Potential Etiologies: Findings From the ASERF Systemic Symptoms in Women – Biospecimen Analysis Study: Part 4. Aesthet Surg J. 2023;
8. Deva A. Personal Communication – Scientific Presentation, The Aesthetic Meeting 2023, Miami. Breast Implant Illness: Where Do We Stand Now. Sunrise Session; Annual Meeting of The Aesthetic Society, Miami Beach, FL, May 2, 2023.
9. Bird GR, Niessen FB. The Effect of Explantation on Systemic Disease Symptoms and Quality of Life in Patients With Breast Implant Illness: A Prospective Cohort Study. Sci Rep. 2022; 12(1 ): 21073;; PMID: 36473891; PMCID: 29 PMC9726875
10. Tanna N, Calobrace MB, Clemens MW, Hammond DC, Nahabedian MY, Rohrich RJ, Zhang BH, Bregman D, Perry AD. Not All Breast Explants Are Equal: Contemporary Strategies in Breast Explantation Surgery. Plastic and Reconstructive Surgery. 2021; 147(4): 808-818;
11. Gerzenshtein J. The Dishonesty of Referring to Total Intact Capsulectomy as “En Bloc” Resection or Capsulectomy. Plastic and Reconstructive Surgery. 2020; 145( 1 ): 227 e-228e;
12. McGuire P, Clauw DJ, Hammer J, Haws M, Adams Jr WP. A Practical Guide to Managing Patients With Systemic Symptoms and Breast Implants. Aesthet Surg J. 2022; 42(4): 397-407;

« »